Psychedelic substances are undergoing a renaissance. As they have been out-of-bounds for public research for half a century, the development process has been driven by drug user communities. With the prospect of a legalization of psychedelics, the data collected by users about toxicity, dosage, etc. have been turned into billion-dollar assets. Know-how stemming from stigmatized user communities...
As the consumers push towards use of natural substances for whole body health increases, and as the dependence upon prescription drugs shows no abatement, substances such as psilocybin (magic mushrooms) have emerged as acceptable methods to treat ailments previously addressed by prescription drugs. In addition to medical solutions provided naturally, many of these substances (primarily...
Given the number of people who are treated for depression each year and the knowledge that treatments work differently for everyone, there is a pressing need to provide a variety of treatment options. Although psychedelic research had been halted for a few decades due to recreational abuse, there has been revived interest due to its therapeutic potential in the treatment of mood disorders and...
Recent evidence shows significant potential for therapies involving psychedelic substances such as psilocybin and MDMA to improve clinical outcomes for patients experiencing various mental disorders. However, research to date focuses almost exclusively on adults. I argue that adolescents should be included in research into psychedelic therapies. First, I demonstrate the pressing need for novel...
Lifetime psychedelic substance use has previously been linked to nature relatedness and pro-environmental behaviour. Yet, participants’ responses to the self-report measures in these studies may have been affected by stereotypical associations or confirmation bias. We therefore re-examined this link by measuring three pro-environmental dependent variables: nature relatedness, concerns about...
The recent surge in recreational (non-medical) use of nitrous oxide (N 2 O, also known as ‘laughing gas’) often by inhaling it from balloons, has attracted the attention of some politicians with calls to control its possession under the United Kingdom (UK) Misuse of Drugs Act 1971 (currently selling, but not possession, for recreational use is controlled under the Psychoactive Substances Act...
The concept of cyberdelics emerged in the 1980s and 1990s as an umbrella term denoting the nexus connecting cybernetic (digital) technologies and psychedelic (mind manifesting) drugs. Cyberdelic technologies, in particular the then newly emerging field of virtual reality, were touted by psychedelic cultural icons including Timothy Leary and Terence McKenna as auguring a new era of digital...
The past decade has witnessed a rapid growth of research on the basic science and clinical understanding of psychedelics. This chapter provides an overview of the human behavioral pharmacology of psychedelics focusing on three prototypic classic psychedelics-psilocybin, lysergic acid diethylamide (LSD), and dimethyltryptamine (DMT). A brief historical overview of the classic psychedelics and...
The nature of consciousness is considered one of science's most perplexing and persistent mysteries. We all know the subjective experience of consciousness, but where does it arise? What is its purpose? What are its full capacities? The assumption within today's neuroscience is that all aspects of consciousness arise solely from interactions among neurons in the brain. However, the origin and...
Classic psychedelics, including psilocybin, lysergic acid diethylamide (LSD), dimethyltryptamine, and mescaline, and entactogens/empathogens, especially 3,4-methylenedioxymethamphetamine, have received renewed attention in psychiatric research and may be developed into medications for such indications as anxiety, depression, cluster headache, and posttraumatic stress disorder, among others....